Currentblue cross blue shield - tennesseePolicy N/A

Urine Culture Testing for Bacteria

Customize your policy alerts

Sign up for all blue cross blue shield - tennessee policy alerts

Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs coverage criteria for urine culture testing to detect and characterize bacteriuria/UTI for Blue Cross Blue Shield - Tennessee members, specifying situations in which testing meets or does not meet coverage. It applies to providers ordering urine cultures for pregnant individuals, pre‑urologic procedures, symptomatic patients, and other clinical contexts described.

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

Currentblue cross blue shield - tennesseePolicy N/A

Urine Culture Testing for Bacteria

Customize your policy alerts

Sign up for all blue cross blue shield - tennessee policy alerts

Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

Payerblue cross blue shield - tennessee

PolicyUrine Culture Testing for Bacteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateJul 1, 2023

Next Review DateN/A

Key ActionDocument at least one sign or symptom of UTI/bacteriuria when ordering urine cultures to support coverage.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

CoveredPregnancy coverage

CoveredPre-urologic procedure

CoveredSymptomatic patients

Not coveredGeneral ASB screening

Not coveredFollow-up post-UTI

MultipleGuideline sources

Coverage Criteria for Urine Culture Testing

inv-01: Covered — Covered when ANY of the following are met:

Covered when ANY of the following are met:

Covered indications: 1) Pregnant individuals: urine culture testing (with isolate identification and antibiotic susceptibilities if applicable) for any urinary tract infection, asymptomatic or symptomatic; 2) Prior to undergoing urological interventions which breach the mucosa: urine culture testing in asymptomatic patients; 3) Patients exhibiting at least one sign or symptom of a possible UTI or bacteriuria: urine culture testing (see signs/symptoms list); 4) To assess pyelonephritis: urine culture testing (with identification and susceptibilities if applicable).

Per policy indications and limitations of coverage.

inv-02: Not covered — Not covered when ANY of the following are present (does NOT meet coverage criteria):

Not covered when ANY of the following are present (does NOT meet coverage criteria):

Not covered indications: 1) Asymptomatic urinary tract infection or asymptomatic bacteriuria in all other instances (outside pregnancy and pre‑urologic mucosal breach); 2) Follow-up urine culture testing for an uncomplicated urinary tract infection in patients who show clinical resolution of infection; 3) As part of initial screening for asymptomatic prostatitis; 4) As part of assessment or prognosis of prostate biopsy (routine pre-biopsy cultures not useful based on cited studies).

Policy lists these as not meeting coverage criteria.

inv-03: Guideline-based coverage criteria and clinical indications

Society recommendations summarized below; where multiple societies agree, cultures are generally restricted to symptomatic or high-risk situations.

ASB general rule: Do not screen for or treat asymptomatic bacteriuria (ASB) in most populations, including healthy premenopausal nonpregnant individuals, many older persons, long-term care residents, patients with diabetes, renal transplant recipients >1 month post-transplant, nonrenal solid organ transplant recipients, and patients with spinal cord injury.

Supported by IDSA, AAP, AMDA, EAU and others.

Exceptions where screening/treatment is recommended: Screening and treatment of ASB are recommended for pregnant individuals and prior to urologic procedures that breach the mucosa; urine culture is the recommended diagnostic method in pregnancy.

Supported by USPSTF, IDSA, EAU, Canadian Task Force.

When to perform urine culture for cystitis/pyelonephritis: Perform urine culture and antimicrobial susceptibility testing for suspected acute pyelonephritis, symptoms not resolving or recurring within 4 weeks after treatment, atypical presentations, pregnant patients, and in complicated UTI; obtain culture prior to initiating antibiotics in many pediatric situations.

inv-04: Covered when clinical indications are present — alignment with guideline recommendations (symptomatic, high-risk, pre-procedural, etc.)

Coverage aligned with guideline recommendations — urine culture testing is covered when clinical indications are present and not recommended for routine screening in specified groups.

Situations recommending urine culture: Urine culture is recommended for: symptomatic acute cystitis episodes in patients with recurrent UTIs (obtain urinalysis and culture prior to treatment); pregnant persons (screen once in first trimester); patients undergoing endoscopic urologic procedures associated with mucosal trauma (obtain culture prior to intervention); infants and children with recurrent UTI or infection not responding to treatment within 24–48 hours if no sample sent; when clinical symptoms and dipstick tests do not correlate.

Sources include AUA/CUA/SUFU, USPSTF, IDSA, Canadian Task Force, NICE.

inv-05: Not medically necessary for routine ASB screening in multiple populations

Not recommended / generally not covered as routine screening or for surveillance in asymptomatic patients

Populations for whom screening/treatment of ASB is recommended against: Do not screen for or treat ASB in: infants and children (screening/treating ASB), healthy premenopausal nonpregnant individuals, healthy postmenopausal individuals, older community-dwelling functionally impaired persons, long-term care residents, patients with diabetes, renal transplant recipients >1 month post-transplant, nonrenal solid organ transplant recipients, patients with short-term indwelling urethral catheters (<30 days), patients undergoing elective nonurologic surgery, patients with spinal cord injury — unless exceptions such as pregnancy or pre‑urologic mucosal-breaching procedures apply.

Recommendations from IDSA, EAU, AST, AMMI Canada; labs encouraged to reduce processing of low-value specimens.

Urine culture testing for asymptomatic bacteriuria (ASB) is excluded from coverage except in two situations: when the patient is pregnant or when testing is performed prior to urologic procedures that breach the mucosa. This reflects the policy statement that urine cultures for ASB DO NOT MEET COVERAGE CRITERIA in other circumstances and that pregnancy and pre‑procedural mucosal breach are explicit exceptions where testing is appropriate.

Routine screening or surveillance urine cultures in asymptomatic individuals are not recommended and do not meet coverage in many settings. Professional societies (including the AAP, EAU and IDSA) advise against surveillance cultures for ASB because they provide no demonstrated benefit and may lead to unnecessary antibiotic exposure; this recommendation applies broadly to populations such as many elderly persons, patients with diabetes, and residents of long‑term care facilities.

Guideline panels consistently identify two key exceptions where screening and treatment of ASB are recommended: pregnant persons (screen and treat) and patients undergoing endoscopic urologic procedures associated with mucosal trauma (screen and treat prior to the procedure). The EAU and IDSA guidelines explicitly endorse these exceptions and specify urine culture as the diagnostic method in pregnancy and before mucosa‑breaching interventions.

Per Choosing Wisely guidance from SHEA and related statements, do not perform urinalysis, urine culture, blood culture, or C. difficile testing unless patients have signs or symptoms of infection. Testing without compatible clinical features risks inappropriate care and potential downstream harms.

Routine pre‑prostate biopsy urine cultures and treatment of asymptomatic bacteriuria are not supported as medically necessary by the cited literature and policy statement; studies have found no clear clinical benefit from obtaining routine preoperative cultures for prostate biopsy, and the policy specifies that such routine pre‑biopsy cultures DO NOT MEET COVERAGE CRITERIA.

Multiple societies recommend against screening for or treating ASB in many populations (for example, healthy nonpregnant adults and numerous older or chronically ill groups). Consequently, ordering urine cultures or treating ASB in these populations is not supported by guideline evidence and is considered inconsistent with best practice.

Do not collect urine specimens for culture from adults who lack urinary tract symptoms or fever unless they are pregnant or are scheduled for genitourinary instrumentation where mucosal bleeding is expected. The Association of Medical Microbiology and Infectious Diseases Canada specifically advises against culture collection in asymptomatic adults except in these exceptions.

Coding and Test Interpretation

Bacteriuria colony count threshold

Colony count threshold10^5 bacteria/ml of urine (definition used for interpreting culture results)

Use in interpretationThreshold cited as the bacteriuria definition applied when assessing single positive culture reliability (80% single-culture reliability)

Source test typeApplies to quantitative urine culture methods used to detect bacteriuria

Provider Actions, Documentation, and Billing Implications

Denial Risk

Ordering in Asymptomatic Patients — Denial Risk

Ordering urine cultures in asymptomatic patients is discouraged and may lead to unnecessary antibiotic use and claim denials. Do not collect urine specimens for culture from adults who lack symptoms localizing to the urinary tract or fever unless they are pregnant or are undergoing genitourinary instrumentation where mucosal bleeding is expected.

Asymptomatic adults (not pregnant and not undergoing genitourinary instrumentation): urine culture is NOT recommended and may be denied.
Pregnant individuals: screening and treatment of asymptomatic bacteriuria MEETS COVERAGE CRITERIA.
Pre‑procedural testing: obtain urine culture prior to urologic procedures that breach the mucosa (meets coverage).

Denial Risk

Inappropriate Testing Without Symptoms

Urine testing (urinalysis, urine culture, blood culture or C. difficile testing) should not be performed unless patients have signs or symptoms of infection. Performing cultures or other tests without clinical indications contributes to antibiotic overuse, adverse events, resistant organisms, and C. difficile infection.

Definitions and Test Types

Bacteriuria / UTI

DefinitionBacteriuria: presence of bacteria in the urine; UTI: infection of urinary system that may be symptomatic or asymptomatic

Included infection typesCystitis, pyelonephritis, urosepsis, urethritis

Male-specific infectionsIncludes prostatitis and epididymitis as male-specific presentations

Uncomplicated vs Complicated UTI

Uncomplicated UTIAcute, sporadic or recurrent cystitis limited to non‑pregnant women with no relevant anatomic/functional urinary tract abnormalities or comorbidities

Complicated UTI (contrast)All other UTIs (men, pregnant individuals, catheterized patients, renal disease, immunocompromised, anatomic/functional abnormalities)

Background

Bacteriuria refers to the presence of bacteria in the urine and may be symptomatic (urinary tract infection) or asymptomatic (ASB). The clinical purpose of urine culture is to detect and identify bacterial pathogens and to provide susceptibility information to guide therapy when infection is suspected. Presence of bacteriuria or pyuria alone does not by itself establish symptomatic infection, and indiscriminate culture of asymptomatic individuals can lead to unnecessary antibiotic use and harms such as resistance and C. difficile infection.

Policy Summary

Payerblue cross blue shield - tennessee

PolicyUrine Culture Testing for Bacteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateJul 1, 2023

Next Review DateN/A

Key ActionDocument at least one sign or symptom of UTI/bacteriuria when ordering urine cultures to support coverage.

SourceLink

On This Page

Supported by EAU, AAP, NICE, CUA.

Pediatric febrile infants: For febrile infants (2–24 months) requiring antimicrobials or not low-risk, obtain urine specimen for culture via catheterization or suprapubic aspiration before antibiotics; if low likelihood, monitoring without testing may be sufficient.

Supported by AAP and CPS.

Recurrent UTI in women: For recurrent uncomplicated cystitis, obtain urinalysis and urine culture with each symptomatic episode prior to treatment; omit surveillance cultures in asymptomatic patients with recurrent UTIs.

Supported by AUA/CUA/SUFU and CUA guidance.

Laboratories may implement analytic interventions to reduce processing of low‑value specimens from asymptomatic patients.

Documentation Required

Clinical Documentation Required

Document at least one sign or symptom of UTI or bacteriuria in the medical record to support urine culture testing. Acceptable signs/symptoms include fever, urgency, frequency, dysuria, suprapubic tenderness, pyuria, hematuria, cloudy urine, flank pain, nausea/vomiting, chills, pelvic pressure, change in urine smell, or other abnormal urinalysis findings.

If testing is performed, include the specific sign or symptom in the clinical note to support medical necessity.

Documentation Required

Use of Urinalysis and When to Obtain Culture

Use urinalysis (dipstick for nitrite and leukocyte esterase and/or laboratory microscopy) as an initial screen to guide the need for culture. In perioperative or contamination‑concern settings, obtain urine microscopy accompanying urine culture. For recurrent symptomatic cystitis episodes, obtain urinalysis and urine culture with susceptibility testing prior to initiating treatment.

If urinalysis is negative (fresh specimen <1 hour) and clinical suspicion is low, monitoring may be reasonable rather than immediate culture (AAP guidance).
Positive microscopy findings in perioperative settings should be confirmed with culture and sensitivity.
For recurrent UTI (symptomatic), obtain culture and sensitivity with each episode before treatment.

Step Therapy

Step Therapy / Prior Authorization

Step therapy: No step‑therapy or prior authorization requirements are specified for urine culture testing in this policy. Follow clinical criteria and documentation requirements described above.

If payer benefit documents impose prior authorization, follow those payer‑specific rules; this policy does not add step therapy.
Coverage determinations depend on member benefits at time of request.

Clinical implicationUncomplicated cases typically do not require routine culture except in specified situations (see guideline recommendations)

Complicated UTI (cUTI)

Definition of cUTIAn infection in a patient with host factors (e.g., diabetes, immunosuppression) or anatomical/functional urinary tract abnormalities (e.g., obstruction, incomplete voiding) that make eradication more difficult

Associated factorsVesicoureteral reflux, recent instrumentation, UTI in males, pregnancy, healthcare-associated infection

Diagnostic methodLaboratory urine culture is the recommended method to determine clinically significant bacteriuria in suspected cUTI

Asymptomatic bacteriuria (ASB)

ASB definitionPresence of bacteria in urine without signs or symptoms of urinary tract infection

Pregnancy riskIn pregnancy, ASB is associated with increased risk of adverse outcomes (eg, preterm birth) and warrants screening and treatment

Symptom distinctionASB differs from symptomatic UTI because bacteriuria/pyuria alone do not confirm symptomatic infection

ASB: guideline recommendations on screening and treatment

General guideline stanceDo not screen for or treat ASB in most populations (infants/children, healthy nonpregnant adults, many older adults, patients with diabetes, many transplant recipients, spinal cord injury patients)

Recommended exceptionsScreening and treatment recommended for pregnant individuals and prior to urological procedures that breach the mucosa (urine culture is the diagnostic method of choice in pregnancy)

Pre-procedure requirementEAU states a urine culture must be taken prior to urologic interventions that breach the mucosa

Asymptomatic bacteriuria (overview)

ASB summaryASB = bacteria in urine without symptoms; guideline recommendations address screening and treatment across populations

Consensus directionMultiple societies (IDSA, EAU, WHO, USPSTF) generally recommend against routine screening/treatment of ASB except in pregnancy and certain peri-procedural contexts

Clinical consequenceOveruse of screening/treatment for ASB can lead to antimicrobial resistance and adverse outcomes; document indications when ordering cultures

Enhanced urine testing

Enhanced culture methodsEnhanced urine culture techniques can improve detection of clinically relevant organisms compared to traditional culture

Multiplex PCRMultiplex PCR–based molecular testing demonstrated noninferiority to urine culture with faster turnaround and detection of organisms missed by culture

Clinical utility noteEnhanced methods may detect more polymicrobial infections and identify bacteria in symptomatic patients with negative standard cultures